Adoptive T cell immunotherapy has shown promise in humans, as seen in the persistent and complete clinical responses observed in patients with leukemia undergoing allogeneic hematopoietic stem cell transplantation followed by the adoptive transfer of donor T lymphocytes 1 , as well as in patients with solid cancer after adoptive transfer of autologous tumor-specific cytotoxic T lymphocytes (CTLs) 2, 3 . However, several hurdles remain before adoptive immunotherapy can become a broadly applicable therapeutic approach. Tumorassociated antigens are often self antigens, and, thus, lymphocytes with the potential to recognize cancer cells with a sufficiently high avidity are usually deleted or anergized to prevent detrimental autoimmunity. If rare high-avidity tumor-specific lymphocytes can be isolated from a patient with cancer, their expansion to the numbers sufficient for therapy generally requires long-term culture, which is often incompatible with the treatment of rapidly growing tumors and which may result in lymphocyte terminal differentiation and reduced activity.
Adoptive T cell immunotherapy has shown promise in humans, as seen in the persistent and complete clinical responses observed in patients with leukemia undergoing allogeneic hematopoietic stem cell transplantation followed by the adoptive transfer of donor T lymphocytes 1 , as well as in patients with solid cancer after adoptive transfer of autologous tumor-specific cytotoxic T lymphocytes (CTLs) 2, 3 . However, several hurdles remain before adoptive immunotherapy can become a broadly applicable therapeutic approach. Tumorassociated antigens are often self antigens, and, thus, lymphocytes with the potential to recognize cancer cells with a sufficiently high avidity are usually deleted or anergized to prevent detrimental autoimmunity. If rare high-avidity tumor-specific lymphocytes can be isolated from a patient with cancer, their expansion to the numbers sufficient for therapy generally requires long-term culture, which is often incompatible with the treatment of rapidly growing tumors and which may result in lymphocyte terminal differentiation and reduced activity.
To overcome these difficulties, the α-and β-chain genes from high-avidity TCRs were cloned from tumor-specific CTLs and genetically inserted into large numbers of human T lymphocytes to impart specificity for autologous tumor cells 4 . Initial clinical studies showed the feasibility and safety of TCR gene transfer, but the therapeutic results have been disappointing compared to those from the infusion of naturally isolated and expanded tumor-specific T cells [5] [6] [7] . This probably reflects the limitations of current gene transfer technologies, which often do not establish stable high levels of expression of the exogenous TCR chains and cannot fully redirect T cell specificity. In fact, the tumor-specific α and β TCR chains are added to mature lymphocytes that already express an endogenous TCR. Thus, the transduced cells express four different TCR chains that compete for binding to components of the CD3 complex-the rate-limiting factor controlling the translocation of paired TCR chains to the cell surface-leading to reduced assembly of the tumor-specific TCR at the plasma membrane. Such dual-specific T cells show impaired function, with a lower avidity for targets expressing either the tumor antigen or the ligand for the endogenous TCR. This problem is further exacerbated by the potential for inappropriate pairing of exogenous and endogenous TCR chains, which limits the assembly of proper tumor-specific TCR and leads to the assembly of new TCRs that have not been subjected to tolerance mechanisms and, thus, have unpredictable specificities, including potential autoreactivity 8, 9 . Indeed, the risk of severe autoimmune toxicity resulting from the formation of self-reactive TCRs by the mispairing of endogenous
The transfer of high-avidity T cell receptor (TCR) genes isolated from rare tumor-specific lymphocytes into polyclonal T cells is an attractive cancer immunotherapy strategy. However, TCR gene transfer results in competition for surface expression and inappropriate pairing between the exogenous and endogenous TCR chains, resulting in suboptimal activity and potentially harmful unpredicted antigen specificities of the resultant TCRs. We designed zinc-finger nucleases (ZFNs) that promoted the disruption of endogenous TCR b-and a-chain genes. Lymphocytes treated with ZFNs lacked surface expression of CD3-TCR and expanded with the addition of interleukin-7 (IL-7) and IL-15. After lentiviral transfer of a TCR specific for the Wilms tumor 1 (WT1) antigen, these TCR-edited cells expressed the new TCR at high levels, were easily expanded to near purity and were superior at specific antigen recognition compared to donor-matched, unedited TCR-transferred cells. In contrast to unedited TCR-transferred cells, the TCR-edited lymphocytes did not mediate off-target reactivity while maintaining their anti-tumor activity in vivo, thus showing that complete editing of T cell specificity generates tumor-specific lymphocytes with improved biosafety profiles. a r t i c l e s 8 0 8 VOLUME 18 | NUMBER 5 | MAY 2012 nature medicine and exogenous chains has been recently highlighted in a mouse model closely mimicking the clinical setting 10 . Current strategies addressing these hurdles aim to promote the preferential assembly and surface expression 11, 12 of the exogenous α and β chains, for example, by using mouse instead of human TCR constant regions, which can enhance homologous pairing but which have proven immunogenic 13 ; by incorporating additional cysteines into the exogenous chains to promote homologous pairing and enhance the stability of the exogenous TCR; and/or by codon-usage optimization of the exogenous TCR genes 14 . These strategies increase exogenous TCR expression but fall short of ensuring the high expression levels that are required for high-avidity tumor-specific effectors and, most crucially, do not eliminate mispairing with the endogenously expressed TCR 15 .
To overcome these limitations, we report a new strategy based on ZFNs to edit T cell specificity at the DNA level by knocking out the endogenous TCR. ZFNs are engineered endonucleases composed of a tandem array of C 2 H 2 zinc finger DNA-binding domains, which can be designed to selectively bind a DNA sequence of choice, coupled to the catalytic domain from the type IIS restriction enzyme FokI 16 to introduce a DNA double-strand break (DSB) at a predetermined genomic site. DSBs are predominantly repaired by non-homologous end joining (NHEJ), which is an error-prone process that often introduces nucleotide deletions or insertions (indels) at the site of the break and, consequently, can lead to gene disruption if the ZFN-induced DSB is targeted to a protein-coding sequence [17] [18] [19] [20] . Our approach, the TCR gene editing, combines the permanent and heritable somatic knockout of the endogenous TCR genes by transient exposure to ZFNs with the transfer of tumor-specific TCR by state of the art lentiviral vectors. We evaluated TCR gene editing in central memory T (T CM ) lymphocytes, which are highly clonogenic, and have been shown to have a capacity for self-renewal (and are thus less prone to exhaustion) and enhanced anti-tumor potential [21] [22] [23] [24] . We found that the TCR-edited cells had enhanced tumor-killing activity, with sharply reduced non-specific alloreactivity compared to matched cells that underwent conventional TCR gene transfer.
RESULTS

Efficient disruption of TRBC genes by ZFNs in human T cells
To edit T cell specificity, we first designed a pair of ZFNs (Supplementary Table 1 ) targeting a sequence found within the TCR β chain that is conserved between the β1 and β2 constant-region genes (TRBC1 and TRBC2; Fig. 1a ) to disrupt the functional TCR β chain gene. We determined the binding specificity of each ZFN using Systematic Evolution of Ligands by Exponential Enrichment (SELEX; Supplementary Table 2) . We used integrase-defective lentiviral vectors (IDLVs) to transiently express the TRBC-targeting ZFNs in lymphocytes (TRBC-ZFN IDLVs; Fig. 1b) 18, 19 . In Jurkat cells, we observed a vector-dose-dependent abrogation of cell-surface expression of the TCR-CD3 complex in up to 20% of the treated cells (Fig. 1c) . A mismatch-selective endonuclease assay (Cel1 assay) confirmed these results at the genetic level, with up to 26% of the TRBC alleles (18% of the TRBC1 and 8% of the TRBC2 alleles) being disrupted at the ZFN target site in the treated cells (Fig. 1d) .
To extend this observation, we activated and sorted T cells from the peripheral blood of healthy donors using beads conjugated with antibodies to CD3 and CD28 (baCD3/CD28) and cultured cells in the presence of IL-7 and IL-15 (5 ng ml −1 ). After 48 h, we exposed the activated T cells to increasing doses of the TRBC-ZFN IDLVs for 24 h. We observed abrogation of the cell-surface expression of the TCR-CD3 complex in up to 7% of the treated cells (Fig. 1e) . A Cel1 analysis of the DNA from cells treated with TRBC-ZFN IDLVs cells showed that up to 6% of the TRBC1 alleles and up to 7% of the TRBC2 alleles carried mutations at the ZFN target site, which is consistent with the disruption of either allele and the observed loss of CD3 surface expression. In cells sorted for loss of CD3 expression, the frequency of TRBC1 and TRBC2 disruption at the DNA level was >30% and >40%, respectively, which is more than the minimal expected level of 25% each, considering that only one out of four alleles is expressed in each cell and that disruption of that one allele is sufficient to abrogate CD3 surface expression (Fig. 1f) . Amplification and sequencing of the TRBC1 and TRBC2 DNA from treated lymphocytes confirmed the occurrence of indels at the ZFN target site, resulting in the disruption of the targeted genes (Fig. 1g) .
Expansion and purification of TRBC-disrupted T lymphocytes Because memory T lymphocytes are less dependent on TCR signals for homeostatic proliferation than are naive T cells 25 , we investigated whether homeostatic cytokines could promote the survival and growth of previously activated cells in the absence of TCR expression and CD3 surface expression (CD3 − cells). Notably, the TRBC-ZFN-treated cells expanded in cultures supplemented with low-dose IL-7 and IL-15 ( Fig. 2a) , with the proportion of CD3 − cells remaining stable for more than 50 d in the absence of TCR triggering. In the absence of cytokines, both CD3 − and CD3 + cells died within 7 d (data not shown), indicating that homeostatic cytokines are required for T cell survival. Thus ZFN exposure was well tolerated in primary human lymphocytes and resulted in the stable disruption of the targeted TRBC gene. CD3 − cells did not proliferate in response to the TCR-dependent mitogen phytohaemagglutinin (PHA) and were rapidly overgrown by the responding CD3 + lymphocytes (Fig. 2b) .
We found no phenotypic differences between CD3 + and CD3 − lymphocytes, which both had similar CD4:CD8 ratios and seemed to acquire T CM surface phenotypes in culture, as evidenced by high expression of CD62L, CD27, CD28 and IL-7 receptor α (IL-7Rα) (Fig. 2c) . Sorted CD3 − cells (Fig. 2d) expanded in response to IL-7 and IL-15 for more than 3 weeks with growth rates similar to those of CD3 + cells (Fig. 2e) , confirming in a pure population of CD3 − cells that homeostatic cytokines do not require TCR signaling to promote the survival and proliferation of previously activated cells. These data show the successful generation of a new population of T lymphocytes that have the phenotypic characteristics of T CM lymphocytes but that have permanently disrupted expression of TCR.
TCR-b editing results in high-avidity tumor-specific T cells We next assessed whether the endogenous TCR-deficient lymphocytes could be further manipulated to generate tumor specific T cells. We selected a TCR specific for the WT1 antigen, which is a therapeutically relevant antigen that contributes to oncogenesis and is broadly overexpressed by leukemias and many solid tumors. We used codonoptimized, human leukocyte antigen A2 (HLA-A2)-restricted TCR α-and β-chain complementary DNAs specific for the WT1 126-134 peptide (WT1-TCR) that had been modified to incorporate matched cysteines in the constant regions to facilitate homologous pairing and high levels of expression 26 . To promote robust and coordinate expression of the α and β TCR chains in transduced lymphocytes, we generated integrating lentiviral vectors encoding both chains under a bidirectional promoter derived from the human phosphoglycerate kinase (PGK) gene (Fig. 3a) 27 .
We first treated T lymphocytes with TRBC-ZFN IDLVs to disrupt the endogenous TRBC gene. We sorted the resulting CD3 − cells and successfully transduced them (49.5% ± 30% (mean ± s.d.) transduction efficiency, n = 4 transductions) with WT1-TCR lentiviral vector, indicating that these cells were permissive to further genetic manipulation. Expression of the transferred WT1-TCR rescued the surface translocation of CD3, which was coexpressed in balanced proportion with the WT1-TCR Vβ21 chain in these TCR-β-edited cells (Fig. 3b) . In contrast to the matched unedited TCR-transferred lymphocytes (Fig. 3b) , TCR-β-edited cells expressing WT1-TCR could be enriched to >90% purity using polyclonal stimulation, indicating that surface expression of the transferred TCR-CD3 complex was necessary and sufficient to promote TCR-mediated expansion (compare to Fig. 2b) . The exogenous Vβ21 chain was expressed in TCR-β-edited lymphocytes at up to twofold higher mean levels than in the unedited TCR-transferred cells and reached similar expression levels as those of the endogenous Vβ21 chain from control T cells (Fig. 3c) . The expression of the Vβ21 chain was stably maintained in culture (Fig. 3d) . Accordingly, after transduction with the same dose of WT1-TCR lentiviral vector, up to 22% of the TCR-β-edited lymphocytes bound the WT1 126-134 pentamer, as compared to only 2.6% of the unedited TCRtransferred cells (Fig. 3c) Theoretically, surface re-expression of the endogenous TCR α chain may still occur in TCR-β-edited cells after TCR gene transfer. To directly assess the potential for residual mispairing in TCR β-chain-disrupted lymphocytes, we transduced CD3 − cells using a lentiviral vector encoding only the WT1-specific TCR β-chain gene and the truncated low-affinity nerve growth factor receptor (∆LNGFR) marker (WT1-TCR-β/∆LNGFR-LV). Despite the absence of a WT1-specific α chain, which is required for correct WT1-TCR pairing, we detected expression of the Vβ21 chain in up to 84% of ∆LNGFR + TRBC-disrupted cells (Fig. 3f) . This result shows that even a cysteine-modified TCR β chain, which is required to complex with an α chain for surface expression, can efficiently mispair with the endogenous TCR α chain when expressed in a cell with endogenous TRBC disruption.
Full TCR-a/b gene editing results in high-avidity T cells
To eliminate the potential for TCR chain mispairing, we designed another pair of ZFNs targeting the constant region of the TCR α chain (TRAC) gene (Fig. 4a) and obtained TCR-α-edited T lymphocytes using the same protocol described above for TCR-β editing (Supplementary Fig. 1 ). We then developed a strategy for complete editing of both TCR-α and TCR-β (TCR-α/β editing) that permitted the rapid isolation of the engineered cells at each sequential step of TCR chain disruption or replacement. This strategy made use of a lentiviral vector to stably express either the α or β WT1-specific TCR chain and used IDLVs or adenoviral vectors (AdVs) to transiently express TRBC-or TRAC-targeting ZFNs (TRBC-ZFN AdV or TRAC-ZFN AdV) in lymphocytes. Whereas CD3 − cells were efficiently generated with both of the ZFN-expressing vectors we tested (Supplementary Fig. 2 ), using AdVs was more efficient, and, therefore, we selected the AdVs for the purpose of complete TCR editing (Fig. 4b) . After AdV transduction, ZFN activity was transient in the treated cells and was detectable only for the first 2-3 d after infection, peaking at 24 h after infection (Supplementary Fig. 3 ).
For the TCR-α/β editing, we first exposed cells harvested from healthy donors to TRAC-ZFN AdV after activation with baCD3/CD28 and culture in the presence of IL-7 and IL-15, and the resulting CD3 − cells (36% ± 13% CD3 − cells (mean ± s.d.)) were sorted 5-8 d after ZFN transduction, when surface protein turnover allows for discriminating CD3 − cells and ZFN activity is no longer detectable because of vector dilution during cell proliferation. We transduced CD3 − cells (65% ± 31% (mean ± s.d.) transduction efficiency) with a lentiviral vector encoding the WT1-TCR α chain under the PGK promoter (WT1-TCR α chain lentiviral vector). We then sorted the cells with rescued CD3 expression, stimulated them with baCD3/CD28 and exposed them to TRBC-ZFN AdV. The second round of ZFN exposure yielded 19% ± 8% (mean ± s.d.) newly CD3 − cells, indicating that primary T lymphocytes are permissive to multiple rounds of ZFN treatment. We sorted the CD3 − cells and transduced them (25% ± 15% (mean ± s.d.) transduction efficiency, n = 4 experiments) with a WT1-TCR β chain lentiviral vector. Expression of the transferred WT1 β chain again rescued the surface translocation of CD3, which was coexpressed in balanced proportion with the WT1-TCR β chain in the TCR-edited cells (Fig. 4b) . TCR-α/β-edited cells could be enriched to near purity by polyclonal stimulation after TCR gene transfer (Fig. 4b) and homogenously expressed the high levels of the WT1-specific TCR that are required to bind the WT1 126-134 HLA-A2 pentamer (Fig. 4c) . These results indicate that surface expression of the transferred TCR-CD3 complex in cells edited for both TCR-α and TCR-β is necessary and sufficient to promote the expansion of the cells with the desired antigen specificity. We confirmed the concomitant disruption of the α and β endogenous TCR chains in cells edited for both TCR-α and TCR-β using a Cel1 assay (Supplementary Fig. 4) . We used the consensus DNAbinding site experimentally determined using SELEX for the TRBCand TRAC-ZFNs for the bioinformatic prediction of the 15 most likely off-target sites for each ZFN set in the human genome. Cel1 assays performed on T lymphocytes edited for TCR-α only, TCR-β only or both TCR-α and TCR-β revealed no detectable signs of NHEJ (1% limit of detection) at any of these 30 genomic sites, suggesting a high rate of target specificity for both of the ZFN sets ( Supplementary  Figs. 5 and 6) . We found no phenotypic differences in the TCRtransferred and the TCR-α/β-edited lymphocytes, which had a preferential T CM surface phenotype (Supplementary Fig. 7a ) and, after stimulation in the absence of co-stimulation, expanded and differentiated with similar kinetics (Fig. 4d and Supplementary Fig. 7b ).
TCR-a/b-edited cells are functional and highly tumor specific
To verify their function and avidity, we compared cells edited for both TCR-α and TCR-β and those edited for TCR-β only to unedited cells, which we transduced with the WT1-TCR lentiviral vector and which we selected for high transgene expression, for the ability to recognize HLA-A2 + and HLA-A2 − WT1 + targets. Similar to the cells edited for TCR-β only, TCR-α/β-edited lymphocytes were superior to the TCR-transferred lymphocytes at recognizing specific WT1 + HLA-A2 + targets (Fig. 4e) . Full editing of both TCR-α and TCR-β was required to completely abrogate off-target reactivity (Fig. 4f) . We confirmed these results on clones that could be isolated and expanded with similar efficiencies from TCR-α/β-edited cells and from TCR-transferred cells, indicating that the editing process does not impair the expansion or responsiveness of T lymphocytes (Supplementary Fig. 8) . We confirmed the high specificity and lytic capacity of TCR-α/β-edited cells by challenge with HLA-A2 + and HLA-A2 − WT1 + acute myeloid leukemia (AML) blasts harvested from patients (Fig. 4g) .
To confirm that the TCR-α and TCR-β editing process abrogated the off-target reactivity of the gene-modified cells, we infused donor-matched TCR-transferred, TCR-α/β-edited or unmanipulated cells into 10-to 12-week-old nonobese diabetic severe combined immunodeficient γ chain knockout (NSG) mice that had been conditioned with 175 cGy irradiation. Six of the six mice receiving unmanipulated T cells and four of the five mice infused with TCR-transferred lymphocytes developed lethal graft-versus-host disease (GvHD) within 2 weeks after the infusion, whereas none of the mice receiving TCR-α/β-edited cells (n = 7) developed GvHD in the 4 weeks of follow up after infusion (Fig. 5a-c) . All experimental groups showed substantial and similar engraftment rates (Fig. 5d) . Notably, despite the fact that gene-modified cells homogenously expressed high levels of the WT1-specific TCR before infusion, expression of the transgenic TCR was significantly lower in TCR-transferred cells than in TCR-α/β-edited lymphocytes harvested from the mice (Fig. 5e) . This observation suggests a selective in vivo expansion of T cells expressing alloreactive TCR pairs, rather than transgenic tumor-specific TCR, in TCR-transferred cells, a condition that was prevented by abrogating endogenous TCR expression by the editing process. Finally, for a comprehensive assessment of the safety and antitumor efficacy of cells edited for both TCR-α and TCR-β, we infused matched TCR-transferred, TCR-α/β-edited or unmanipulated cells into 10-to 12-week-old NSG mice conditioned with 175 cGy irradiation and infused with WT1 + leukemic blasts harvested from two HLA-A2 + patients with AML. In this model, mice are expected to die either from GvHD or leukemia. Event-free survival, defined as survival in the absence of GvHD and leukemia, was superior in the cohort of mice receiving TCR-α/β-edited cells than in mice infused with TCR-transferred cells (P < 0.05) or those receiving unmanipulated lymphocytes (P < 0.01; Fig. 5f ). The anti-tumor activity was dependent on WT1-TCR expression and was significant in mice treated with TCR-transferred cells (P < 0.05) and those treated with TCR-α/β-edited cells (P < 0.05) when compared to untreated mice and mice treated with untransduced lymphocytes. However, mice infused with unedited TCR-transferred cells suffered rapid-onset and lethal GvHD (Fig. 5a) . Indeed, the observed mortality in mice receiving TCR-transferred cells was caused entirely by GvHD, whereas 50% and 100% of the deaths in mice that received unmanipulated lymphocytes or PBS, respectively, were caused by leukemia growth. These results indicate the advantage of cells edited for both TCR-α and TCR-β, compared to TCR-transferred cells, in mediating a safe anti-leukemia response in vivo.
DISCUSSION
Suboptimal activity toward their specific target and the generation of potentially harmful unpredicted specificities are common drawbacks of TCR gene transfer in human T cells 9 . Our results show that combining ZFN-driven disruption of the endogenous TCR α-and β-chain genes with lentiviral delivery of a tumor-specific TCR results in the successful and complete editing of primary CD8 + T cell specificity. Because both disruption and replacement are performed at the genetic level, edited TCR specificity is stable and is transmitted to cell progeny. The absence of the endogenous TCR chains on TCRedited cells allows for a more robust and homogenous expression of the introduced tumor-specific TCR, resulting in a higher avidity for the specific target, and completely overcomes the safety issues raised by TCR mispairing.
The advantage of these edited cells is best exemplified by the much higher fraction of WT1 126-134 pentamer binding cells observed in the edited cells compared to that found in unedited TCR-transferred lymphocytes. Accordingly, TCR-α/β-edited cells showed a higher activity than TCR-transferred cells against relevant targets, including blasts harvested from patients with AML. Most notably, the cells edited for both TCR-α and TCR-β had sharply reduced activity against nonspecific targets, further emphasizing the utility of preventing the formation of mispaired TCRs and suggesting that such TCR-edited cells may possess improved safety with respect to the risk of inducing autoimmune diseases. In a mouse preclinical model, the mispairing of endogenous and exogenous TCR chains has been clearly linked to severe toxicity 10 . Although molecular modifications of the exogenous TCR genes can reduce the extent of this mispairing, strategies that are able to completely abrogate this risk have not been previously reported. Recently, the expression of siRNA has been proposed to specifically downregulate endogenous TCR expression. However, this approach reduced, but did not eliminate, the expression of the endogenous TCR 12 . Here we show that even cysteine modification of the TCR chains, one of the most promising approaches to address mispairing 26, 28 , is not sufficient to abrogate this unwanted effect. The strategy we describe here allows for the rapid generation of large numbers of tumor-specific T cells expressing high functional levels of only the desired TCR, thus eliminating the risk of TCR mispairing. In a humanized mouse model, we found no GvHD after infusion of TCR-α/β-edited lymphocytes whereas the infusion of TCR-transferred lymphocytes induced lethal GvHD within 2 weeks in the majority of infused mice, showing in vivo that forced expression in human T cells of an exogenous TCR per se does not prevent alloreactivity, even when the TCR chains include cysteine modifications. Several sequential steps of genetic manipulation ensure complete editing of both TCR-α and TCR-β in the final cellular product. Here, disruption of each TCR chain gene by ZFNs was accomplished separately because (i) the simultaneous expression of four individual ZFNs (two sets) targeting distinct genomic sites had the potential to lead to unwanted ZFN dimer pairings and, therefore, increased off-target activity, at least with some ZFNs 29 , and (ii) identification of the gene-targeted cells took advantage of the dependence of the surface expression of CD3 on the expression of both TCR chains. Surface CD3 expression thus provides a convenient surrogate marker to rapidly select viable cells with the desired gene modification at each disruption or replacement step of the protocol. This approach allows the whole process to be completed within a culture time that is shorter than that reported in some settings to isolate and expand viral-specific T cells 30 and to generate a pure population of antigen-specific T cells in the absence of antigenic stimulation.
To our knowledge, this is the first time that a double genetic disruption that is efficiently followed by gene replacement has been achieved in primary human cells. Notably, the gene editing did not detectably affect the phenotype, function or proliferative potential of the engineered cells. TCR-edited lymphocytes circulating 4 weeks after infusion continued to express high levels of the tumor-specific TCR, suggesting the potential long-term stability of such cells in vivo. Indeed, when challenged in vivo with primary human leukemias, TCR-edited cells showed substantial anti-tumor efficacy and, because they were devoid of off-target reactivity, were superior to TCRtransferred lymphocytes in promoting event-free survival. Further advances in humanization of mouse models, possibly including the in vivo production of human cytokines, may allow for the assessment of the TCR-editing protocol for long-term T cell viability. Clinical trials based on ZFN-mediated disruption of the CCR5 (clinicaltrials. gov identification numbers NCT 00842634 and NCT 01044654) and glucocorticoid receptor (NCT 01082926) genes in T lymphocytes are ongoing, indicating the feasibility of pursuing a ZFN-based therapy for clinical applications 17 . Clinical development of our strategy could thus proceed using well-established protocols for producing genetically engineered T cells for use in humans, and the application of this new approach to modify distinct T cell subpopulations may substantially enhance the therapeutic potential and reduce the possible risk of toxicity of immunotherapy for a variety of cancers. 
ONLINE METHODS
Lentiviral and adenoviral vectors. We designed and assembled TRBC-and TRAC-ZFNs as previously described 16 . The recognition helices used are listed in Supplementary Table 1 . We generated lentiviral vectors encoding TRBCand TRAC-ZFNs from the HIV-derived self-inactivating transfer construct pCCLsin.cPPT.SFFV.eGFP.Wpre, which was packaged by an integrase-defective third-generation packaging construct carrying the D64V mutation in the HIV integrase and pseudotyped by the VSV envelope as described 31 . The Ad5/F35 adenoviral vectors were generated on an E1-E3-deleted backbone. We linked the ZFNs targeting either the TRBC or TRAC gene using a 2A peptide sequence and cloned them into the pAdEasy-1/F35 vector under the control of the cytomegalovirus TetO promoter, and the Ad5/F35 virus for each construct was generated using TREx 293T cells as described 32 . We generated lentiviral vectors encoding both WT1-specific TCR chains and single α21 or β21 WT1-specific TCR chains from the bidirectional self-inactivating transfer vector pCCLsin.cPPT.∆LNGFR.minCMV.hPGK.eGFP.Wpre 27 and from pCCLsin.cPPT.hPGK.eGFP.Wpre, which were packaged by an integrasecompetent third-generation construct and pseudotyped by the VSV envelope as described 31 . The codon-optimized, cysteine-modified WT1-TCR α and β chain genes were previously described 26 .
Culture conditions and vector tranductions. We cultured the T2 and Jurkat cell lines in RPMI 1640 (GIBCO-BRL) supplemented with penicillin, streptomycin, glutamine and 10% FBS (BioWhittaker). We obtained human T lymphocytes and fresh leukemia samples from patients with AML after obtaining informed consent according to a protocol approved by the San Raffaele Bioethical Committee. For transduction with ZFN-IDLVs, ZFN-AdVs or WT1-TCR lentiviral vector, we activated and sorted T lymphocytes using magnetic beads conjugated to antibodies to CD3 and CD28 (ClinExVivo CD3/CD28; Invitrogen), following the manufacturer instructions, and grew them in Iscove's Modified Dulbecco's Media (IMDM) (GIBCO-BRL) supplemented with penicillin, streptomycin, 10% FBS and 5 ng ml −1 of each IL-7 and IL-15 (PeproTech) as previously described 23 . To test resistance of CD3 − cells to polyclonal TCR-mediated stimulation, we cultured cells with 2 µg ml −1 PHA in IMDM supplemented with penicillin, streptomycin, 10% FBS, 5 ng ml −1 of each IL-7 and IL-15 and 100 international units ml −1 of IL-2.
We performed transductions with the indicated doses of IDLVs or lentiviral vectors, measured as HIV Gag protein p24 equivalents, 48 h after activation. Vector infectivity ranged from 1 × 10 4 to 5 × 10 4 transducing units per ng of p24 by vector DNA titration of 293T cells. For transduction, we plated T lymphocytes at 2.5 × 10 6 cells ml −1 and infected them with the indicated doses of lentiviral vector, IDLVs or AdV for 24 h. We then cultured the lymphocytes at 10 6 cells ml −1 for expansion.
We sorted Vβ21 + cells, CD3 − and CD3 + cells using selection columns and anti-FITC or anti-CD3 MACS MicroBeads (Miltenyi Biotec), respectively, following the manufacturer instructions.
For TCR-β or TCR-α editing, ZFN-IDLV-or ZFN-AdV-transduced lymphocytes, sorted as CD3 − cells, were subsequently transduced with the lentiviral vector encoding both WT1-TCR chains and were expanded by polyclonal stimulation 33 .
TCR-a/b editing. BaCD3/CD28 activated T lymphocytes were treated with TRAC-ZFN AdV (multiplicity of infection (MOI) 10 3 ), and CD3 − lymphocytes were sorted and transduced with WT1-TCR-α LV (MOI 65). After a second cycle of baCD3/CD28 stimulation, α-edited lymphocytes were treated with TRBC-ZFN AdV (MOI 10 4 ) at 30 °C according to a cold-shock protocol previously described 34 to increase efficiency. CD3 − cells were sorted and transduced with WT1-TCR-β LV (MOI 100). During the entire protocol, cells were cultured in the presence of 5 ng ml −1 of each IL-7 and IL-15.
Staining for surface markers. For T lymphocyte phenotyping, we used FITC-, PE-, PerCP-, APC-, PE-Cychrome 7-or Pacific Blue-conjugated antibodies directed to human CD3, CD8, CD27, CD28, IL-7Rα (BD Biosciences), CD62L (EXBIO) or Vβ21 (Beckman Coulter). Cells (5 × 10 5 ) were incubated with antibodies for 15 minutes at 4 °C and washed with PBS containing 1% FBS. WT1 126-134 pentamer PE (Proimmune) was used following manufacturer instructions. To measure IL-7Rα expression, cells were washed and cultured in the absence of cytokines for 18 h before staining with fluorochrome-conjugated antibodies. Samples were run through a FACS Canto II flow cytometer (BD Biosciences), and data were analyzed by Flow Jo software (Tree star Inc).
Molecular analyses.
To measure the mutations consequent to NHEJ at the ZFN target site, we used the Mismatch selective Cel1 nuclease assay 18 with the following primers: TRBC1, 5′-CTGAACAAGGTGTTCCCACCC-3′ and 5′-GT GTGCGCTGGTTCCTTTCTT-3′; TRBC2, 5′-CCTGGCCACAGGCTTC TACC-3′ and 5′-CCACCTTGTCCACTCTGGCTT-3′; TRAC, 5′-GGG CAAAGAGGGAAATGAGA-3′ and 5′-CAATGGATAAGGCCGAGACC-3′.
For vector copy number assessment, we performed quantitative PCR on 200 ng of genomic DNA using primers and probes complementary to the vector backbone sequence (primer binding site) and human telomerase gene, with the latter amplification being used as a normalizer, as previously described 18 . Standard curve for lentiviral integrations was generated by serial dilutions of DNA from human cell lines containing a known number of vector integrations.
Functional assays and in vivo studies. We evaluated the functional activity of the T cells 3 weeks after stimulation using a cytotoxicity assay or a γIFN ELISpot assay as described 35 .
For the 51 chromium release assay, effectors were incubated in V-bottom 96-well plates for 5 h with T2 cells pulsed with the WT1 126-134 or pp65 [495] [496] [497] [498] [499] [500] [501] [502] [503] peptides (Proimmune) and for 18 h with γIFN-cultured (200 UI ml −1 ) human primary leukemic blasts, which were previously labeled with 51 chromium. Specific lysis was expressed according to the following formula: 100 × (average experimental cpm − average spontaneous cpm)/(average maximum cpm − average spontaneous cpm).
For γIFN ELISpot, we plated cells in Multiscreen HTS 96-well filtration plates (Millipore) at the concentration of 2 × 10 4 cells per well with T2 cells pulsed with the WT1 126-134 or pp65 495-503 peptides (Proimmune) or unrelated PBMCs for 18 h at a stimulator-to-responder ratio of 1. We then washed cells and added 1µg ml −1 of the biotinylated human γIFN antibody (mAb 7-B6-1, MABTEC). After 2 h of incubation, we washed plates with PBS-Tween and added streptavidin-HRP (ZYMED, Invitrogen) diluted 1:2,500 in PBS for 1.5 h. After another PBS-Tween wash, we added 100 µl of the 3-amino-9-ethylcarbazole substrate (ready-to-use AEC solution, Invitrogen) and incubated plates for 12 min. The reaction was stopped by the addition of tap water, and the spots were quantified by KS-Elispot Reader (Zeiss).
For the in vivo studies, we obtained 10-to 12-week-old female NSG mice from Jackson Labs. The experimental protocol was approved by the internal committee for animal studies of San Raffaele Scientific Institute (Institutional Animal Care and Use Committee). We resuspended the cells in 250 µl IMDM medium with 5% FBS and infused them intravenously into the mice after sub-lethal irradiation (175 cGy). We monitored the mice for clinical GvHD 3 times per week as described 36, 37 . The following signs were included in the clinical index: weight loss (0 for a weight loss <5% of the total body weight, 1 for 5-10% weight loss and 2 for >10% weight loss), hunching (scored 0-2), activity (0-2), fur texture (0-2) and skin integrity (0-2), yielding a maximum possible index score of 10. We euthanized moribund mice for ethical reasons. We determined human chimerism every 3 d for the first week using flow cytometry after bleeding from the tail vein. Human chimerism was calculated as follows: human chimerism (%) = (huCD45 + /(huCD45 + + mCD45 + )] × 100, where the hu prefix indicates human and the m prefix indicates mouse. The expression of WT1-specific TCRs was quantified on gated (huCD45 + ) human cells by flow cytometry. For the in vivo assessment of anti-tumor efficacy, primary AML blasts, harvested after informed consent from two HLA-A2 + patients with AML, were infused intravenously at the dose of 5-10 × 10 6 cells per mouse into mice preconditioned with 175 cGy irradiation. After T cell infusion (days 0-2), mice were monitored 3 times per week for GvHD or leukemia occurrence, which was defined by the appearance of circulating blasts (>1%).
Statistical analyses.
Statistical analyses on the functional data were performed using a Mann-Whitney U test for non-parametric data and using a twoway analysis of variance test for the peptide titration experiments.
